Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 411-417

  Chung, David T ^a   Tsai, Cheng Yuan ^a   Chen, Shu Jen ^a   Chang, Li Wen ^a   King, Chi Hsin R ^a   Hsu, Ching Hung ^a   Chiu, Kit Mui ^a,b   Tan, Hao Chen ^a,c   Chang, Yu Ting ^a   Hsu, Ming Chu ^a  

^a TaiGen Biotechnology Co Ltd   (Taiwan)

^b AMGEN INC   (United States)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEMONOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TG 873870; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSGEUSIA; DYSMENORRHEA; DYSPEPSIA; DYSURIA; ELECTROCARDIOGRAM; ERYTHEMA; EYE DISEASE; FEMALE; FLATULENCE; FLUSHING; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; INJURY; LABORATORY TEST; LIPID DIET; MALE; MINIMUM INHIBITORY CONCENTRATION; MUSCLE TIGHTNESS; NAUSEA; NONCARDIAC CHEST PAIN; NORMAL HUMAN; OCULAR HYPEREMIA; OTALGIA; PANCREATITIS; PLASMA CONCENTRATION-TIME CURVE; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STEADY STATE; URINE ODOR;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; DERMATITIS, CONTACT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENZYMES; FEMALE; HEADACHE; HUMANS; MALE; QUINOLONES; YOUNG ADULT;

EID: 73849145677     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00683-09     Document Type: Article

References (34)

1. Allen, A., E. Bygate, M. Vousden, S. Oliver, M. Johnson, C. Ward, A.-J. Cheon, Y. S. Choo, and I.-C. Kim. 2001. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob. Agents Chemother. 45:540-545.
2. Allen, A., E. Bygate, S. Oliver, M. Johnson, C. Ward, A. J. Cheon, Y. S. Choo, and I. C. Kim. 2000. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 44:1604-1608.
3. Andriole, V. T. 1999. The future of the quinolones. Drugs 58(Suppl. 2):1-5.
4. Chen, S. J., L. Lin, and L. W. Chang. 2007. Analysis of antibacterial response of nemonoxacin (TG-873870) against major pathogens from respiratory tract and skin infections, abstr. 441. Abstr. 45th Infect. Dis. Soc. Am.
5. Chow, A. T., C. Flowler, R. R. Williams, N. Morgan, S. Kaminski, and J. Nataranjan. 2001. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45:2122-2125.
6. Chow, C. P., C. P. Sambuco, and A. M. Hoberman. 2007. Phototoxicity of nemonoxacin (TG-873870) in hairless mice, abstr. A-28. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
7. Chow, C. P., C. Y. Tsai, C. F. Yeh, and S. J. Chen. 2007. In vitro metabolism and interaction of nemonoxacin (TG-873870) on human hepatic CYP3A4, abstr. A-27. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
8. Chow, C. P., C. Y. Tsai, and Y. M. Chen. 2007. Cardiovascular safety evaluation of nemonoxacin (TG-873870) in dogs and monkeys, abstr. B-823. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
9. Coleman, C. I., J. V. Spencer, J. O. Chung, and P. Reddy. 2002. Possible gatifloxacin-induced fulminant hepatic failure. Ann. Pharmacother. 36:1162-1167.
10. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
11. Gajjar, D. A., A. Bello, Z. Ge, L. Christopher, and D. M. Grasela. 2003. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob. Agents Chemother. 47:2256-2263.
12. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, NY.
13. Gough, K., M. Hutchinson, O. Keene, B. Byron, S. Ellis, L. Lacey, and J. McKellar. 1995. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetic UK joint working party. Drug Inform. J. 29:1039-1048.
14. Hsu, C. H., Y. M. Chen, and C. P. Chow. 2008. Fertility and early embryonic developmental toxicity of nemonoxacin after oral administration to rats, abstr. F1-2056. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
15. Hsu, C. H., Y. M. Chen, and C. P. Chow. 2008. Systemic hypersensitivity test of nemonoxacin, a novel potent broad-spectrum non-fluorinated quinolone in guinea pigs, abstr. F1-2055. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
16. King, C. H. R., L. Lin, and R. Leunk. 2008. In vitro resistance development to nemonoxacin for Streptococcus pneumoniae, abstr. C1-1971. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
17. Lauderdale, T. L., Y. R. Shiau, J. H. Lai, H. C. Chen, and C. H. King. 2007. In vitro antibacterial activity of nemonoxacin (TG-873870), a new nonfluorinated quinolone, against clinical isolates, abstr. E-1635. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
18. Lin, L., K. M. Chiu, and T. K. Chung. 2007. Single-dose safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers, abstr. 439. Abstr. 45th Infect. Dis. Soc. Am.
19. Lipsky, B. A., and C. A. Baker. 1999. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis. 28:352-364.
20. Lode, H., K. Borner, and P. Koeppe. 1998. Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 27:33-39.
21. Lubasch. A., I. Keller, K. Borner, P. Koeppe, and H. Lode. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 47:2600-2603.
22. Noreddin, A. M., A. A. Reese, M. Ostroski, D. J. Hoban, and G. G. Zhanel. 2007. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Clin. Ther. 29:2685-2689.
23. Owens, R. C., Jr., and P. G. Ambrose. 2005. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 41(Suppl. 2):S144-S157.
24. Pankuch, G. A., K. Kosowska-Shick, P. McGhee, C. H. R. King, and P. C. Appelbaum. 2008. Comparative antistaphylococcal activity of nemonoxacin, a novel broad-spectrum quinolone, abstr. C1-189. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
25. Roychoudhury, S., and B. Ledoussal. 2002. Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens. Curr. Drug Targets Infect. Disord. 2:51-65.
26. Schentag, J. J., A. K. Meagher, and A. Forrest. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: in vitro and animal models. Ann. Pharmacother. 37:1287-1298.
27. Schentag, J. J., A. K. Meagher, and A. Forrest. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann. Pharmacother. 37:1478-1488.
28. Smith, B. P., F. R. Vandenhende, K. A. DeSante, N. A. Farid, P. A. Welch, J. T. Callaghan, and S. T. Forgue. 2000. Confidence interval criteria for assessment of dose proportionality. Pharm. Res. 17:1278-1283.
29. Stahlmann, R. 2002. Clinical toxicological aspects of fluoroquinolones. Toxicol. Lett. 127:269-277.
30. Stass, H., A. Dalhoff, D. Kubitza, and U. Schühly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065.
31. World Health Organization. 2006. Proposed INN list 96. World Health Organ. Drug Inf. 20:292.
32. Zhanel, G. G., and A. M. Noreddin. 2001. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr. Opin. Pharmacol. 1:459-463.
33. Zhanel, G. G., N. Laing, M. DeCorby, K. Nichol, C. H. R. King, H. Adam, and D. J. Hoban. 2008. Activity of nemonoxacin, an investigational C8-methoxy non-fluorinated quinolone, against Gram-positive cocci obtained from Canadian hospitals: CANWARD 2007, abstr. F1-2057. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
34. Zimpfer, A., A. Propst, G. Mikuz, W. Vogel, L. Terracciano, and S. Stadlmann. 2004. Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch. 444:87-89.